TABLE 1.

Clinical trials of Hydroxychloroquine (HCQ) in patients with COVID‐19 [83, 84, 85, 86, 87]

Ref	Study type (no. of patients)	Duration	Primary outcomes	ICU patients (n/N)	Mortality (n/N)
	Treatment	Control group (no. of patients)	Clinical outcomes	Adverse events (n/N)
49	Prospective open‐label, non‐randomized trial (n = 42)	10 days	Viral load (nasopharyngeal swab): absence or presence of SARS‐CoV‐2 at Day 6	0/36	0/36
	HCQ (200 mg every 8 h) alone (n = 14) or with azithromycin (500 mg on Day 1, 250 mg on Days 2–5; n = 6)	Yes (n = 16)	NR (not reported)	NR
49	Prospective observational study (n = 80)	10 days	Disease progression: need for oxygen or ICU admission	3/80	1/80
	HCQ (200 mg every 8 h) and azithromycin (500 mg on Day 1, 250 mg on Days 2–5)	No	Viral load, hospital length of stay	7/80
49	Randomized Controlled Trial (RCT) (n = 30)	7 days	Viral load (nasopharyngeal swab): presence of SARS‐CoV‐2 at Day 7	0/30	0/30
	HCQ (200 mg every 12 h)	Yes (n = 15)	NR	4/15
49	RCT (n = 62)	5 days	Time to clinical recovery	0/62	0/62
	HCQ (200 mg every 12 h)	Yes (n = 31)	Pulmonary recovery, adverse events	2/31
49	Prospective observational study (n = 11)	10 days	Viral load (nasopharyngeal swab): presence of SARS‐CoV‐2 on Days 5–6	2/11	1/11
	HCQ (200 mg every 8 h) and azithromycin (500 mg on Day 1, 250 mg on Days 2–5)	No	NR	1/11